Rapid progress in collaboration between Pharmaceutical Biology and Aravive in innovative medicines

Today, Aravive and Aravive, a U.S. biotech company, jointly announced that they have decided to further expand their full-scale cooperation in the biopharmaceity pipeline based on rapid progress in the development of the Aravive candidate drug AVB-S6-500 process, pilot amplification and cGMP production.about AVB-S6-500
AVB-S6-500 (formerly code-named Aravive-S6) is a new GAS6-AXL pathline inhibitor for the treatment of cancer and non-malignant fibrosis diseases.
AVB-S6-500 is an innovative bio-candidate drug that suppresses the GAS6-AXL signaling path with high affinity to the GAS6.
that GAS6-AXL signaling is considered a key molecular path path for tumor growth and metastasis, tumor immune escape, and resistance to other cancer drugs.
preclinical studies, inhibition of AXL-GAS6 not only showed single-drug efficacy, but also synergized with a variety of anticancer therapies, including radiotherapy, immuno-oncology drugs, and drugs that block DNA replication and repair. Aravive expects to launch phase I clinical trials of AVB-S6-500 in the first quarter of 2018.
August 2017, The Wuxi base of Pharmaceuticals became the first cGMP production base in China to complete the pre-approval inspection of FDA biopharmaceased drugs, laying a solid foundation for the rapid development of commercial production of innovative biopharmaceas products.